Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2012 | short review

New developments in gastrointestinal cancer—ASCO 2012

verfasst von: Cornelis J. A. Punt, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The treatment of gastrointestinal cancer involves many medical disciplines, and several novel strategies and drugs are currently the subject of clinical studies. The most relevant results on studies in gastrointestinal cancer as presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) are reviewed here.
Vorheriger Artikel Late lung metastasis of primary endometrial cancer
Nächster Artikel Transient elevation of serum carcinoembryonic antigen level in a patient with hypothyroidism
Literatur
1.
Waddell TS, et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). ASCO Annual Meeting 2012 (abstract LBA4000).
2.
Bajetta E, et al. Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer. ASCO Annual Meeting 2012 (abstract LBA4001).
3.
Conroy T, et al. Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial. ASCO Annual Meeting 2012 (abstract LBA4003).
4.
Glynne-Jones R, et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: results of ACT II. ASCO Annual Meeting 2012 (abstract 4004).
5.
Rimassa L, et al. Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT). ASCO Annual Meeting 2012 (abstract 4006).
6.
Grothey A, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26:5326–34.PubMedCrossRef
7.
Cohn AL, et al. Clinical outcomes in bevacizumab-treated patients with metastatic colorectal cancer: results from ARIES observational cohort study and confirmation of BRiTE data on bevacizumab beyond progression. ASCO Annual Meeting 2010 (abstract 3596).
8.
Arnold D, et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). ASCO Annual Meeting 2012 (abstract 3503).
9.
Van Cutsem E, et al. ESMO/ECCO Annual Meeting 2011 (abstract 6LBA).
10.
Allegra C, et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: a phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. ASCO Annual Meeting 2012 (abstract 3505).
11.
Tournigand C, et al. Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial. ASCO Annual Meeting 2012 (abstract LBA3500).
12.
Van Cutsem E, et al. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). ASCO Annual Meeting 2012 (abstract 3502).
13.
Siu LL, et al. Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): the NCIC Clinical Trials Group and AGITG CO.20 trial. ASCO Annual Meeting 2012 (abstract 3504).
14.
Bendell JC, et al. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2011;29:4394–400.PubMedCrossRef
15.
Bendell JC, et al. Results of the X-PECT study: a phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). ASCO Annual Meeting 2012 (abstract LBA3501).
16.
Venderbosch S, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol. 2011;18:3252–60.PubMedCrossRef
17.
Faron M, et al. Impact on survival of primary tumor resection in patients with colorectal cancer and unresectable metastasis: pooled analysis of individual patients’ data from four randomized trials. ASCO Annual Meeting 2012 (abstract 3507).
18.
Nordlinger B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.PubMedCrossRef
19.
Nordlinger B, et al. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. ASCO Annual Meeting 2012 (abstract 3508).
Metadaten
Titel
New developments in gastrointestinal cancer—ASCO 2012
verfasst von
Cornelis J. A. Punt, MD, PhD
Publikationsdatum
01.12.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0049-5

Weitere Artikel der Ausgabe 4/2012

Update on lung cancer from the annual meeting of the American Society of Clinical Oncology 2012

  • short review

Late lung metastasis of primary endometrial cancer

  • case report

“Stem cell transplantation: its importance today”

  • short review

Primary angiosarcoma of the breast with a poor prognosis primarily masquerading as hemangioma

  • case report

Significant heterogeneity between centers during early evaluation of the first Turkish multi-centric study in the treatment of childhood acute lymphoblastic leukemia

  • short review

Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors

  • short review